Welcome to our dedicated page for Beyondspring SEC filings (Ticker: BYSI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Untangling BeyondSpring’s biotech disclosures can feel like decoding a lab manual. Every 10-K details the cash runway for Plinabulin’s Phase 3 trials, while 10-Q updates bury dose-limiting toxicity data deep in footnotes. If you’ve ever searched “BeyondSpring insider trading Form 4 transactions” or “how to read a BeyondSpring quarterly earnings report 10-Q filing,” you know the challenge.
Stock Titan resolves it. Our AI engine turns pages of technical language into concise highlights, giving you “BeyondSpring SEC filings explained simply” in minutes. Receive alerts on “BeyondSpring Form 4 insider transactions real-time,” track FDA-driven “BeyondSpring 8-K material events explained,” and dive into a “BeyondSpring annual report 10-K simplified” summary that calls out R&D spend, milestone payments, and going-concern disclosures. Whether you’re reviewing “BeyondSpring executive stock transactions Form 4,” requesting a “BeyondSpring earnings report filing analysis,” or comparing segment revenue shifts, our platform surfaces the numbers and context that matter.
Why focus on BeyondSpring? Drug-development costs, milestone-based licensing revenue, and equity stakes in SEED Therapeutics make each filing uniquely data-dense. Stock Titan’s expert layer flags where non-cash R&D credits affect margins, highlights trial-enrollment shifts that alter cash burn, and links proxy-statement tables—search “BeyondSpring proxy statement executive compensation”—directly to dilution scenarios. Real-time EDGAR feeds, AI-powered summaries, and clean navigation mean you spend less time scrolling and more time valuing BYSI’s oncology pipeline. Understanding BeyondSpring SEC documents with AI has never been this straightforward.
Decheng Capital-related funds and manager Dr. Xiangmin Cui reported insider sales of BeyondSpring Inc. (BYSI) ordinary shares over three consecutive days in September 2025. The filings show Fund III sold 5,410 shares on 09/22/2025 at a weighted average price of $1.83, 4,106 shares on 09/23/2025 at $1.72, and 2,256 shares on 09/24/2025 at $1.68, for a total of 11,772 shares sold across the three transactions. After these sales, Fund III beneficially owned 1,847,561 shares. The Form 4 also discloses indirect holdings by affiliated vehicles: Fund II holds 1,617,409 shares and Decheng Capital Global Healthcare Fund (Master) holds 891,734 shares. The filings state the reported prices are weighted averages for multiple transactions within specified ranges and identify Decheng Capital management entities and Dr. Cui as the reporting persons.
Decheng Capital entities reported insider dispositions of BeyondSpring Inc. (BYSI) ordinary shares across three days in September 2025. Decheng Capital China Life Sciences USD Fund III sold 2,304 shares on 09/17/2025 at a weighted average price of $1.83, 5,307 shares on 09/18/2025 at $1.74, and 3,656 shares on 09/19/2025 at $1.79, totaling 11,267 shares sold and leaving Fund III with 1,859,333 shares. The filing also shows indirect holdings of 1,617,409 shares by Decheng Capital China Life Sciences USD Fund II and 891,734 shares by Decheng Capital Global Healthcare Fund (Master), LP. Footnotes explain weighted average pricing ranges and that GP entities and Dr. Xiangmin Cui may be deemed beneficial owners but disclaim direct ownership except for pecuniary interest.
Insider sales by Decheng-affiliated funds in BeyondSpring (BYSI) The filing shows Decheng Capital entities and Dr. Xiangmin Cui reported a series of open-market dispositions of BeyondSpring ordinary shares in mid-September 2025. Decheng Capital China Life Sciences USD Fund III, L.P. sold a total of 4,110 shares across trades on 09/12/2025, 09/15/2025 and 09/16/2025 at weighted-average prices reported as $1.85, $1.84 and $1.88 respectively. After those sales, Fund III’s reported beneficial ownership was 1,870,600 shares. The filing also reports indirect beneficial ownership of 1,617,409 shares by Decheng Capital China Life Sciences USD Fund II, L.P. and 891,734 shares by Decheng Capital Global Healthcare Fund (Master), LP. Signatures indicate Dr. Xiangmin Cui as manager executing the filing on behalf of the Decheng entities on 09/16/2025.
BeyondSpring Inc. held its 2025 annual meeting of shareholders on September 15, 2025. Shareholders representing 21,852,265 ordinary shares, or approximately 54.19% of the 40,322,320 outstanding shares entitled to vote as of the July 25, 2025 record date, were present or represented by proxy. Shareholders ratified the appointment of CBIZ CPAs P.C. as the companys independent registered public accounting firm for the fiscal year ending December 31, 2025, with 21,831,390 votes in favor, 14,265 against, and 6,610 abstentions.
Decheng Capital affiliates and Dr. Xiangmin Cui reported sales of BeyondSpring Inc. (BYSI) ordinary shares across three days in September 2025. The filings show Fund III sold 9,050 shares on 09/09/2025 at a weighted average price of $1.97, 8,176 shares on 09/10/2025 at $1.93, and 3,820 shares on 09/11/2025 at $1.90 (weighted averages covering ranges $1.90–$2.00 and $1.87–$1.94). After these transactions Fund III beneficially owned 1,874,710 shares. Related Decheng entities report additional indirect holdings: Fund II 1,617,409 shares and Global Healthcare Fund 891,734 shares. The Form 4s identify Decheng Capital Management entities and Dr. Cui as reporting persons and include standard disclosure footnotes about beneficial ownership and weighted average pricing.
Decheng Capital-related entities reported sales of BeyondSpring Inc. (BYSI) ordinary shares. Decheng Capital China Life Sciences USD Fund III, L.P. sold 803 shares on 09/04/2025 at a weighted-average price of $1.82, 1,106 shares on 09/05/2025 at $1.86, and 7,090 shares on 09/08/2025 at $1.93, leaving Fund III with 1,895,756 shares beneficially owned. The filing also reports indirect holdings of 1,617,409 shares by Decheng Capital China Life Sciences USD Fund II, L.P. and 891,734 shares by Decheng Capital Global Healthcare Fund (Master), LP. Footnotes state the reported prices are weighted averages across specified price ranges and that the general partners and Dr. Xiangmin (Cui) may be deemed to beneficially own the funds' holdings. The Form 4 is signed by Xiangmin Cui on 09/08/2025.
Decheng Capital-affiliated funds and Dr. Xiangmin Cui reported sales of BeyondSpring Inc. (BYSI) ordinary shares in late August and early September 2025. The filing shows Decheng Capital China Life Sciences USD Fund III, L.P. sold 800 shares on 08/29/2025, 2,800 shares on 09/02/2025 and 1,270 shares on 09/03/2025 at weighted-average prices in the $1.67–$1.84 range, reducing Fund III’s reported beneficial ownership to 1,904,755 shares.
Other related entities retain beneficial holdings: Decheng Capital China Life Sciences USD Fund II, L.P. holds 1,617,409 shares and Decheng Capital Global Healthcare Fund (Master), LP holds 891,734 shares. Footnotes explain the holdings are held directly by the named funds, GP entities and Dr. Cui may be deemed to beneficially own such securities, and the reported prices are weighted averages across multiple transactions.
Decheng Capital entities reported multiple small open-market sales of BeyondSpring Inc. (BYSI) ordinary shares between August 26 and August 28, 2025. Fund III sold 2,000 shares on 08/26/2025 at a weighted-average price of $1.79, 1,300 shares on 08/27/2025 at $1.78, and 809 shares on 08/28/2025 at $1.81; those disposals reduced Fund III's beneficial holding to 1,909,625 shares. The filing discloses additional indirect holdings: Fund II holds 1,617,409 shares and Decheng Global Healthcare (Master) LP holds 891,734 shares. The reporting chain shows common control through Decheng Capital management entities and Dr. Xiangmin (Xiangmin) Cui as manager, with standard disclaimers of beneficial ownership by general partners except for pecuniary interest. Footnotes state the prices are weighted averages across multiple transactions within disclosed price ranges.
Decheng Capital entities and Dr. Xiangmin Cui reported a series of open-market sales of BeyondSpring Inc. (BYSI) ordinary shares in August 2025. Decheng Capital China Life Sciences USD Fund III, L.P. sold a total of 5,710 ordinary shares across 08/21/2025–08/25/2025 at weighted average prices of approximately $1.79, $1.75, and $1.77, leaving Fund III with 1,913,734 shares beneficially owned. Related Decheng vehicles also report indirect holdings of 1,617,409 and 891,734 shares respectively. All holdings are reported as indirect and the filings disclose customary disclaimers of direct beneficial ownership by the general partners and manager.
FAQ
What is the current stock price of Beyondspring (BYSI)?
What is the market cap of Beyondspring (BYSI)?
